MedDataX Logo

Clearance of NNAL and Cotinine From Second-hand Smoke in Hair and Urine

NCT ID: NCT00863824

Last Updated: 2023-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2009-07-31

Study Completion Date

2010-05-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate how long it takes for NNAL and cotinine, markers of second hand smoke, to clear the human body.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Cell DNA Adducts in Smokers

NCT03285893

Lung Cancer
COMPLETED

Study of Hair Samples From Patients With Cancer

NCT00899691

Unspecified Adult Solid Tumor, Protocol Specific
COMPLETED

Assessment of Early Genetic Changes in Smokers

NCT00200408

Cancer of Head and Neck Smoking
TERMINATED

Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

NCT00898313

Lung Cancer
RECRUITING

Ethnic/Racial Differences in Metabolism and DNA Adduct Formation

NCT03421678

Lung Cancer
WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the study is to investigate how long it takes for NNAL and cotinine, both specific markers of second hand tobacco smoke exposure to clear the human body.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy Caucasians and African-Americans 19 years of age or above, how are ready to quit smoking

Exclusion Criteria

* Anyone who is not a Caucasian or an African-American, below 19 years of age, and is currently taken prescription medication.
Minimum Eligible Age

19 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centers for Disease Control and Prevention

FED

Sponsor Role collaborator

University of Nebraska

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chandran Achuatn, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Nebraska

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0121-09-EP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

DNA Repair and Genetic Susceptibility to Lung Cancer
NCT00611598 COMPLETED
Genetic Susceptibility to Bladder Cancer
NCT00848289 ACTIVE_NOT_RECRUITING
Hair Isotope Analysis for Early Cancer Detection
NCT07006909 NOT_YET_RECRUITING
Plasma Circulating Deoxyribonucelic Acid (DNA) as a Response Marker
NCT00318604 UNKNOWN
A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma
NCT01063998 TERMINATED
DNA Repair, p53 and Apoptosis Phenotypes in Lung Cancer
NCT00339859 COMPLETED
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT04099290 RECRUITING
Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis
NCT02441140 TERMINATED NA
Biomarker Identification for Bladder Cancer Patients
NCT02053662 TERMINATED
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881 RECRUITING
Cell-free DNA in Hereditary And High-Risk Malignancies 1
NCT04261972 ACTIVE_NOT_RECRUITING
Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"
NCT03071809 TERMINATED
Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202
NCT01503619 COMPLETED
Biomarkers of Renal Dysfunction in Neuroblastoma Survivors
NCT03947346 COMPLETED
Circulating DNA in Surgically Treated NSCLC
NCT04037150 UNKNOWN
Biomarkers in Patients With Head and Neck Cancer
NCT01466257 COMPLETED
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
NCT03662204 COMPLETED
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 RECRUITING
A Study to Explore Biomarkers in Samples of Blood, Urine, Stools, Hair Follicles and Saliva From Patients With Cancer
NCT05574738 RECRUITING
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
NCT02245100 COMPLETED
Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer Patients
NCT02186236 COMPLETED
Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients
NCT02853097 TERMINATED
The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
NCT02450448 COMPLETED
ctDNA for Early Detection of Recurrence in Melanoma
NCT06246227 ACTIVE_NOT_RECRUITING
CfDNA in Hereditary And High-risk Malignancies 2
NCT06726642 RECRUITING